Deal Health is a single score from 0 to 100 that answers one question: if nothing changes, how likely is this deal to close on time? It’s the most-viewed element in Veyro — reps open it 11 times a day on average — and it’s also the one we get the most thoughtful pushback on. Fair enough. A score that shapes where people spend their week should be explainable, so here’s how it works.
Fourteen signals, four families
Every score is built from 14 Signals grouped into four families. Each family is weighted differently depending on the deal’s stage, its segment and your team’s own historical outcomes.
Engagement — reply latency, meeting cadence, email sentiment, and whether the buyer or the seller is doing most of the talking.
Stakeholders — buyer-side contact count, seniority coverage, and whether an economic buyer has been active in the last 21 days.
Momentum — next steps agreed on calls, mutual action plan progress, and days in stage versus your team’s median.
Commercial — pricing conversations, discount requests, procurement activity, and quote or contract events from your billing system.
Weights aren’t static. A Momentum signal like days-in-stage matters little in early discovery and a great deal in the final two stages. The model learns those shifts from your own closed deals, so a team selling six-month enterprise contracts and a team closing in three weeks get very different scores for the same activity.
Why it disagrees with your gut
The most common complaint we hear is that Deal Health is too harsh on deals a rep feels great about. Often, that’s the point. In our data, deals with a single enthusiastic champion and no economic-buyer activity close on time just 23% of the time. The score isn’t questioning the relationship — it’s pointing out that the relationship is the only thing holding the deal up.
The reverse happens too. Deals that feel quiet to a rep — a buyer who has stopped taking calls while their procurement team actively reviews the contract — often score higher than expected. Sometimes silence means the deal has moved into a part of the organisation the rep can’t see.
Every score now ships with its top three drivers in plain language, so a rep can see exactly why a deal dropped and what would move it back up.
“Deal Health is the first score my team argues with instead of ignoring. That’s how I know it’s useful.”
— Sasha Petrov, VP of Sales, Quillon
Where we’re taking it next
Later this year, Deal Health will learn directly from your won and lost reasons, so the weighting reflects how your buyers buy rather than how the average B2B buyer does. We’re also adding a Veyro Copilot summary you can paste straight into a deal review, and testing a team view that rolls individual scores up into a coverage map, so managers can see which segments carry real risk without scanning deal by deal.
If you have strong opinions about what the score should or shouldn’t count, we’d genuinely like to hear them. Some of our best Signals started as a customer telling us we were wrong.
